Comparison of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Activities when Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections

Hello S. Sader, Robert K. Flamm, Mariliana Castanheira, Rodrigo E. Mendes

JMI Laboratories, North Liberty, Iowa, USA

ANTIMICROBIAL ACTIVITY: 2018

Table 1: Antimicrobial activity of ceftazidime-avibactam and comparator agents tested against Enterobacterales and P. aeruginosa isolated from patients with complicated urinary tract infections in US medical centers (2018)

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>Enterobacterales</th>
<th>P. aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colistin</td>
<td>99.4%</td>
<td>85.2%</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>99.7%</td>
<td>95.1%</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>84.8%</td>
<td>73.4%</td>
</tr>
<tr>
<td>Ceftazidime-avibactam</td>
<td>99.9%</td>
<td>99.1%</td>
</tr>
<tr>
<td>Ceftolozane-tazobactam</td>
<td>90.4%</td>
<td>80.9%</td>
</tr>
</tbody>
</table>

CONCLUSIONS

Ceftazidime-avibactam demonstrated good activity against CRE isolates in the current study. Ceftazidime-avibactam exhibited the broadest overall coverage (Enterobacterales + P. aeruginosa) among the tested agents tested against gram-negative bacilli from patients with cUTI in US hospitals during 2016.

ACKNOWLEDGEMENTS

The authors wish to thank all participants of the International Network for Optimal Resistance Monitoring (INFORM) program for providing isolated isolates.

This study was supported by Allergan. Allergan was involved in the design and decision to present these results, and JMI Laboratories received compensation for services related to preparing the paper. Allergan had no involvement in the collection, analysis, or interpretation of data.

REFERENCES